



Medical Imaging

Formerly Beacon Bioscience

## **Commercial Imaging Corelab Pioneer Joins ICON Medical Imaging**

ICON Medical Imaging (IMI) has announced the recruitment of Dr. James Conklin. Dr. Conklin has been appointed as Senior Vice President for Medical & Scientific Affairs. Dr. Conklin is a serial entrepreneur, who pioneered commercial imaging core laboratories as the founder, CEO and Chairman of Bio-Imaging Technologies; Inc, which he founded in 1990.

Dr. Conklin has been a senior executive including CEO at numerous life science technology companies ranging from genomics to electronic data capture and computer aided detection imaging software. Before founding Bio-Imaging, Dr. Conklin was Vice President of Product Development at Cytogen Corporation, held a senior position at Centocor, Inc and was the Director of the Armed Forces Radiobiology Research Institute (AFRRI) the largest radiobiology research institute in the world with nearly 500 people. In this role, Dr. Conklin was a member of an advisory team to the US Joint Chiefs of Staff, and the Department of Defense representative to the radiation science panel of the White House Office of the President Science and Technology. Dr. Conklin is a Johns Hopkins trained research physician with undergraduate and graduate training in electrical/computer engineering and a master's degree in management. He has been a Professor of Radiology at several medical schools. published over 100 scientific papers and edited four books. Early in his career Dr. Conklin flew Phantom fighter aircraft in the US Air Force.

Dr. Conklin described his new role: "I am delighted to be reunited with my old colleagues and friends. They have taken the medical image core laboratory industry to a new level with outstanding technology, processes and procedures. I am excited to be working in the dynamic and challenging medical imaging arena again and hope to help keep IMI the best and most innovative imaging core laboratory in the industry."

Ted Gastineau, CEO of IMI commented: "We are delighted to be working with Jim again. His experience and diverse industry background are consistent with our planned leadership expansion, adding scientific and medical expertise in the dynamic field of drug development."